Cimzia Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Cimzia (certolizumab pegol) is a PEGylated monoclonal antibody that targets tumor necrosis factor (TNF), used to reduce inflammation and prevent immune system-related damage in certain autoimmune diseases. It is used in treating moderate to severe rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of cimzia are biologics and biosimilars, designed to address the needs of both adult and pediatric patients. Cimzia is distributed through various channels, including hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. Its applications extend to treating conditions such as Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, active psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis.

The cimzia market research report is one of a series of new reports from The Business Research Company that provides cimzia market statistics, including cimzia industry global market size, regional shares, competitors with a cimzia market share, detailed cimzia market segments, market trends and opportunities, and any further data you may need to thrive in the cimzia industry. This cimzia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cimzia market size is expected to see rapid growth in the next few years. It will grow to $6,776.6 million in 2029 at a compound annual growth rate (CAGR) of 17%. The growth in the forecast period can be attributed to rising demand for targeted biologics, increasing patient preference for self-administration devices, growth in biosimilar competition, increasing government healthcare funding, and growing emphasis on personalized medicine. Major trends in the forecast period include shift towards patient-centric drug delivery solutions, adoption of digital health tools for disease management, increasing use of real-world evidence in drug development, growth of telemedicine and home care solutions, and integration of AI in clinical trials.

The growing prevalence of rheumatoid arthritis (RA) is expected to drive the expansion of the cimzia market. RA is a chronic autoimmune disorder where the immune system attacks the body's joint tissues, causing inflammation, pain, and swelling. The rise in RA cases can be linked to an aging population, increasing genetic predisposition, environmental factors such as smoking and pollution, and greater awareness and diagnosis of the condition. Cimzia plays a crucial role in managing RA by providing targeted therapy to reduce inflammation, relieve symptoms, improve patient well-being, and aid in better disease management. For example, in May 2022, the Pain Relief Foundation, a UK-based charity, reported that arthritis and musculoskeletal conditions affect over 17 million people in the UK, leading to 30 million lost working days annually, while chronic pain affects up to 62% of those over 75. Additionally, in February 2024, the Centers for Disease Control and Prevention (CDC) reported that the age-adjusted prevalence of diagnosed arthritis in adults aged 18 and older was 18.9% in 2022, with women (21.5%) more likely to have arthritis than men (16.1%). Therefore, the increasing prevalence of rheumatoid arthritis is driving the growth of the cimzia market.

A key trend in the cimzia market is the development of innovative treatments, such as autoimmune therapy solutions, to address unmet needs in autoimmune disease management, particularly for patients with non-radiographic axial spondyloarthritis (nr-axSpA). Autoimmune therapy solutions aim to restore immune balance and tolerance, often using targeted immunotherapies and cellular therapies. For example, in July 2024, UCB, a Belgium-based biopharmaceutical company, announced the expansion of Cimzia (certolizumab pegol) as a treatment for patients with nr-axSpA. This expansion provides an innovative option for patients who have not yet shown radiographic evidence of the disease but still experience symptoms. Cimzia is the first biologic to receive FDA approval for nr-axSpA, establishing its unique position in autoimmune treatment. This approval offers an important alternative to traditional therapies, improving symptom management and quality of life for patients.

In February 2022, Biogen Inc., a US-based biotechnology company, entered into a licensing agreement with Xbrane Biopharma, a Sweden-based biopharmaceutical company, to develop, manufacture, and commercialize Xcimzane, a biosimilar to Cimzia. This partnership aims to provide more affordable treatment options for patients with rheumatoid arthritis and other conditions, promoting better access to care and contributing to healthcare savings through the availability of a cost-effective alternative to the original drug.

Key player operating in the cimzia market is UCB SA

North America was the largest region in the cimzia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cimzia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cimzia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cimzia market consists of sales of injectable formulations, pre-filled syringes, auto-injectors, and IV infusions. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cimzia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cimzia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cimzia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cimzia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Biologics; Biosimilars
• 2) By Patient Demographics: Adults; Pediatrics
• 3) By Distribution Channels: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Pharmacies
• 4) By Application: Crohn's Disease; Rheumatoid Arthritis; Ankylosing Spondylitis; Active Psoriatic Arthritis; Axial Spondyloarthritis; Plaque Psoriasis
• Companies Mentioned: UCB SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.